Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 6, keine Gesamtzahl für „when“
Suchtreffer
Begriffe & Kennungen
Brukinsa · 4.5 · No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with
Eintrag öffnenBuccolam · 4.8 · The table below lists the adverse reactions reported to occur when oromucosal midazolam was administered in cl
Eintrag öffnenBuvidal · 4.5 · 8 expected to have less effects on buprenorphine metabolism when co-administered with Buvidal as compared to w
Eintrag öffnenBuvidal · 4.5 · Buprenorphine should be used cautiously when co-administered with: • naltrexone and nalmefene: These are opioi
Eintrag öffnenBuvidal · 4.5 · Buprenorphine should be used cautiously when co-administered with: • naltrexone and nalmefene: These are opioi
Eintrag öffnenBysumlog · 4.5 · The physician should be consulted when using other medications in addition to Bysumlog (see section 4.4).
Eintrag öffnenCabometyx · 4.8 · Cabozantinib in combination with nivolumab in first-line advanced RCC Summary of safety profile When cabozanti
Eintrag öffnenCabometyx · 4.8 · Elevated liver enzymes when cabozantinib is combined with nivolumab in RCC In a clinical study of previously u
Eintrag öffnenCabometyx · 4.8 · Physeal widening has been observed in children with open growth plates when treated with cabozantinib.
Eintrag öffnenCalquence · 4.5 · No clinically significant differences in acalabrutinib pharmacokinetics were observed when a 100 mg acalabruti
Eintrag öffnenCalquence · 4.8 · Serious infections when treating patients with Calquence in combination with venetoclax with or without obinut
Eintrag öffnenCalquence · 4.8 · Serious infections when treating patients with Calquence in combination with venetoclax with or without obinut
Eintrag öffnenCapecitabine Accord · 4.5 · Interferon alpha The MTD of capecitabine was 2000 mg/m2 per day when combined with interferon alpha-2a (3 MIU/
Eintrag öffnenCapecitabine Teva · 4.5 · Interferon alpha The MTD of capecitabine was 2000 mg/m2 per day when combined with interferon alpha- 2a (3 MIU
Eintrag öffnenCapecitabine Teva · 4.5 · Radiotherapy The MTD of capecitabine alone using the intermittent regimen is 3000 mg/m2 per day, whereas, when
Eintrag öffnenCellCept · 4.5 · 49 4.4). Conversely, changes of MPA exposure should be expected when switching patients from CsA to one of the
Eintrag öffnenCellCept · 4.5 · Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs,
Eintrag öffnenCellCept · 4.5 · Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs,
Eintrag öffnenCellCept · 4.5 · Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs,
Eintrag öffnenCellCept · 4.5 · Higher aciclovir plasma concentrations were observed when mycophenolate mofetil was administered with aciclovi
Eintrag öffnen